Simplified AIT for allergy to several tree pollens-Arguments from the immune outcome analyses following treatment with SQ tree SLIT-tablet.

"CONFLICT OF INTEREST TB is an advisory board member for and has received speaker's fees from ALK, Novartis and Mylan. HI is a consultant for ALK. PAW, PMG, GL, SG and PSA are employees of ALK."

"Funding information This trial was funded by ALK, Hoersholm, Denmark."

"The clinical trial is identified by ClinicalTrials.gov Identifier EudraCT 2015‐004821‐15, and details of the trial design and patient demographics were reported previously. Briefly, this was a randomized, parallel‐group, double‐blind, placebo‐controlled, multi‐site, phase III field trial with 1:1 randomization between treatment with SQ tree SLIT‐tablet or placebo. Subjects were included on basis of a positive skin prick test response (wheal diameter ≥ 3 mm) to birch (Betula verrucosa) extract, a positive Bet v 1‐specific IgE (≥IgE Class 2; ≥0.7 kUA/L) and moderate to severe allergic rhinoconjunctivitis symptoms during the 2 previous birch pollen seasons. Blood samples were collected from 397 subjects at baseline and after 1, 4, 7 and 9 months of treatment. Collection of blood samples was approved by the local ethics committees approving the trial (EudraCT 2015‐004821‐15) and informed consent was obtained from all subjects donating blood for the immunological tests."